title: Therapeutic alternatives in cutaneous T-cell lymphoma.
abstract: Mycosis fungoides and Sézary syndrome, collectively referred to as cutaneous T-cell lymphoma, are non-Hodgkin's lymphomas that initially appear in the skin. Early-stage disease, limited to the skin, is best treated with sequential topical therapies such as topical nitrogen mustard, psoralen phototherapy (PUVA), or total-skin electron beam therapy. Photopheresis is the first line of therapy for the patient with erythroderma. Systemic therapy is generally reserved for patients with refractory disease and patients who initially present with extracutaneous involvement. Although there are several treatment options for cutaneous T-cell lymphoma, there have been few randomized comparative trials.
authors.affiliation: Department of Medicine, University of Florida College of Medicine, Gainesville.
authors.forename: K B
authors.initials: KB
authors.lastname: Holloway
authors.forename: F P
authors.initials: FP
authors.lastname: Flowers
authors.forename: F A
authors.initials: FA
authors.lastname: Ramos-Caro
mesh_terms: D003131:Combined Modality Therapy; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D008466:Mechlorethamine / Q000627:therapeutic use; D009367:Neoplasm Staging; D011701:PUVA Therapy; D010778:Photochemotherapy; D012176:Retinoids / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*
chemical_list: D012176:Retinoids; D008466:Mechlorethamine; D007372:Interferons